{
  "symbol": "PFE",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1636,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.163
  },
  "top_positive": [
    {
      "sent": "Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9974
    },
    {
      "sent": "Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9974
    },
    {
      "sent": "Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9974
    }
  ],
  "top_negative": [
    {
      "sent": "41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (vaccine) Immunization to prevent primary clostridioides difficile infection sasanlimab (PF-06801591) Combination with Bacillus Calmette-Guerin for high-risk non-muscle-invasive bladder cancer VLA15 (PF-07307405) vaccine (c) Immunization to prevent Lyme disease vepdegestrant (PF-0785\nciclib 2 nd line HR+/HER2- metastatic breast cancer Phase 3 study to a Phase 2 non-registrational study.",
      "score": -0.9931
    },
    {
      "sent": "41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (\nany countries outside the U.S.",
      "score": -0.9893
    },
    {
      "sent": "41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (vaccine) Immunization to prevent primary clostridioides difficile infection sasanlimab (PF-06801591) Combination with Bacillus Calmette-Guerin for high-risk non-muscle-invasive bladde\ntive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU are also enacting the provisions into their domestic law.",
      "score": -0.9876
    }
  ],
  "forward_snippets": [
    "Research and Development Arrangement Research and Development Funding Arrangement with Blackstone \u2013\u2013In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $ 326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments.",
    "We expect costs associated with this initial part of the program to continue primarily through 2025 and to total approximately $ 3.1 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as non-cash asset write downs of which $ 2.4 billion is associated with our Biopharma segment.",
    "We expect costs associated with the additional productivity opportunities to be incurred through 2027 and to total approximately $ 1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation, of which $ 700 million is associated with our Biopharma segment.",
    "We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $ 600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment.",
    "The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $ 1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment."
  ],
  "curated_text": "Symbol: PFE. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Approved June 2021 Approved February 2022 Approved August 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Filed November 2024 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Filed November 2024 Abrysvo (Vaccine) Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV Approved October 2024 Approved March 2025 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (a) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Braftovi (encorafenib), Erbitux \u00ae (cetuximab) and mFOLFOX6 (b) First-line BRAF V600E -mutant mCRC Approved December 2024 Xtandi (enzalutamide) (c) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B without inhibitors Approved October 2024 Approved November 2024 Approved December 2024 Emblaveo (aztreonam-avibactam) (d) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved February 2025 Approved April 2024 Padcev (enfortumab vedotin-ejfv) ( e ) In combination with Keytruda \u00ae(f) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv (g) Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy Approved April 2024 Approved March 2025 Approved March 2025 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (h) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August 2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Adcetris (brentuximab vedotin) (i) Relapsed/refractory diffuse large B-cell lymphoma Approved February 2025 Paxlovid (nirmatrelvir; ritonavir) COVID-19 infection in high-risk children Filed February 2025 Filed January 2025 Filed April 2025 Eliquis (apixaban) (j) Venous thromboembolism (pediatric) Approved April 2025 Approved July 2024 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Top negative sentences: 41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (vaccine) Immunization to prevent primary clostridioides difficile infection sasanlimab (PF-06801591) Combination with Bacillus Calmette-Guerin for high-risk non-muscle-invasive bladder cancer VLA15 (PF-07307405) vaccine (c) Immunization to prevent Lyme disease vepdegestrant (PF-0785\nciclib 2 nd line HR+/HER2- metastatic breast cancer Phase 3 study to a Phase 2 non-registrational study. 41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (\nany countries outside the U.S. 41 The following provides information about additional indications and new drug candidates in late-stage development: PRODUCT/CANDIDATE PROPOSED DISEASE AREA LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS Ibrance (palbociclib) (a) ER+/HER2+ metastatic breast cancer Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC Litfulo (ritlecitinib) Vitiligo Elrexfio (elranatamab) Multiple myeloma double-class exposed Newly diagnosed multiple myeloma post-transplant maintenance Newly diagnosed multiple myeloma transplant-ineligible 2nd line + relapsed refractory multiple myeloma Padcev (enfortumab vedotin) (b) Cisplatin-ineligible/decline muscle-invasive bladder cancer Cisplatin-eligible muscle-invasive bladder cancer Tukysa (tucatinib) HER2+ adjuvant breast cancer 2nd line/3rd line HER2+ metastatic breast cancer 1st line HER2+ maintenance metastatic breast cancer 1st line HER2+ metastatic colorectal cancer Nurtec (rimegepant) Menstrually-related migraine Hympavzi (marstacimab-hncq) Hemophilia (pediatric) Hemophilia (inhibitor cohort) NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT PF-06425090 (vaccine) Immunization to prevent primary clostridioides difficile infection sasanlimab (PF-06801591) Combination with Bacillus Calmette-Guerin for high-risk non-muscle-invasive bladde\ntive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU are also enacting the provisions into their domestic law. Forward-looking snippets: Research and Development Arrangement Research and Development Funding Arrangement with Blackstone \u2013\u2013In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $ 326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments. We expect costs associated with this initial part of the program to continue primarily through 2025 and to total approximately $ 3.1 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as non-cash asset write downs of which $ 2.4 billion is associated with our Biopharma segment. We expect costs associated with the additional productivity opportunities to be incurred through 2027 and to total approximately $ 1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation, of which $ 700 million is associated with our Biopharma segment. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $ 600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $ 1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment."
}